Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kingworld Medicines GroupHKSE:01110 -2.06%43 ROA % is 2.36% as of Dec. 2025, which is 20% below its 10-year median of 2.94. GuruFocus rates HKSE:01110 with a GF Score™ of 43/100 and a GF Value™ of HK$0.50 (Fairly Valued). The stock has 5 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Kingworld Medicines Group ranks worse than 59.77% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Kingworld Medicines Group's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$37 Mil.
Kingworld Medicines Group's average Total Assets over the quarter that ended in Dec. 2025 was HK$1,562 Mil. Therefore, Kingworld Medicines Group's annualized ROA % for the quarter that ended in Dec. 2025 was 2.36%.
The historical rank and industry rank for Kingworld Medicines Group's ROA % or its related term are showing as below:
HKSE:01110'
s ROA % Range Over the Past 10 Years
Min: 0.8 Med: 2.94 Max: 3.85
Current: 0.81
During the past 13 years, Kingworld Medicines Group's highest ROA % was 3.85%. The lowest was 0.80%. And the median was 2.94%.
HKSE:01110's ROA % is ranked worse than 59.77% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 2.08
vs HKSE:01110: 0.81
Kingworld Medicines Group (HKSE:01110) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kingworld Medicines Group ROA % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Kingworld Medicines Group's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kingworld Medicines Group ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Kingworld Medicines Group's ROA % distribution charts can be found below:
* The bar in red indicates where Kingworld Medicines Group's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Kingworld Medicines Group (HKSE:01110) has a ROA % of 2.36% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Kingworld Medicines Group and its competitors. This is 20% below median its historical median of 2.94. Over the past decade, Kingworld Medicines Group's ROA % has ranged from 0.80 to 3.85. According to the industry distribution chart, Kingworld Medicines Group ranks #407 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 59.8%.
Is Kingworld Medicines Group's ROA % too high?
Kingworld Medicines Group's current ROA % of 2.36% is 20% below median its 10-year median of 2.94. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 3.85. The Healthcare Providers & Services industry median ROA % is 2.08. Kingworld Medicines Group's value of 2.36% is 13.5% above this industry median. Based on the distribution chart, Kingworld Medicines Group ranks #407 out of 681 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Kingworld Medicines Group has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kingworld Medicines Group's ROA % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Kingworld Medicines Group ranks #407 out of 681 companies for ROA %. This places Kingworld Medicines Group in the lower half of its industry. The industry median ROA % is 2.08. Kingworld Medicines Group's value of 2.36% is 13.5% above this benchmark. Historically, Kingworld Medicines Group's own ROA % has ranged from 0.80 to 3.85 over the past decade. While the company's 10-year median is 2.94 vs. the industry median of 2.08, Kingworld Medicines Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 2.08, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kingworld Medicines Group's current ROA % of 2.36% is 13.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Kingworld Medicines Group and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kingworld Medicines Group's current ROA % is 2.36%, which is 20% below median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kingworld Medicines Group stock overvalued right now?
Based on GuruFocus' analysis, Kingworld Medicines Group (HKSE:01110) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.50, compared to a current price of HK$0.48 — trading 5% below its estimated fair value. The current ROA % is 2.36%, which is 20% below median its 10-year median of 2.94 and 13.5% above the Healthcare Providers & Services industry median of 2.08. Kingworld Medicines Group's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Kingworld Medicines Group (HKSE:01110), the current ROA % is 2.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kingworld Medicines Group (HKSE:01110) Overvalued in 2026?
Based on GuruFocus' analysis, Kingworld Medicines Group stock appears to be undervalued.
The current stock price of HK$0.48 is trading 5% below its estimated GF Value™ of HK$0.50.
GuruFocus considers Kingworld Medicines Group to be Fairly Valued.
Key valuation signals for HKSE:01110:
ROA %: 2.36% (20% below median its 10-year median of 2.94)
GF Value™: HK$0.50 vs. price of HK$0.48 (5% below fair value)
Industry Position: 13.5% above the Healthcare Providers & Services median (#407 of 681)
No single metric tells the full story. See the HKSE:01110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kingworld Medicines Group Ltd is engaged in the Distribution of pharmaceutical and healthcare products, such as branded imported pharmaceutical and healthcare products in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices carried out in the PRC. It derives the majority of its revenue from the Distribution sales of the pharmaceutical and healthcare products segment.
43GF Score
Get the complete analysis for HKSE:01110
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01110 has been successfully added to your 
